Xiao-Dong Lv

Xiao-Dong Lv

Auto-generated profile, based on publicly available information

Xiao-Dong Lv

Liaoning University of Traditional Chinese Medicine, 79 East of Chongshan Road, Shenyang, 110847, Liaoning, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinics
Verified
Journal Article
Open access
XZXinXin Zhang
XinXin Zhang
LPLi-Jian Pang
Li-Jian Pang
XLXiaoDong Lv
XiaoDong Lv
HZHaoYang Zhang
HaoYang Zhang
The risk factors of bronchiectasis in patients with chronic obstructive pulmonary disease have not yet been established. This systematic review and meta-analysis aimed to investigate and identify potential risk factors for patients with chronic obstructive pulmonary disease accompanied by bronchiectasis. We reviewed eight electronic journal databases from their inception to November 2019 for observational studies with no language restrictions. The Newcastle-Ottawa Scale was applied to evaluate the quality of the literature. Binary variables were pooled using odds ratios and continuous variables using the standardized mean difference with 95% confidence intervals. The confidence of evidence was assessed according to the grading of the recommendations assessment, development, and evaluation method. Eight case-control studies met the inclusion criteria. Tuberculosis history, smoking history, hospitalization stays, admissions in the past year, and duration of symptoms were considered risk factors. In addition, the ratio between the forced expiratory volume in 1s and forced vital capacity, the percentage of forced expiratory volume in 1s, the forced expiratory volume in 1s as a percentage of the predicted value, purulent sputum, purulent mucus sputum, positive sputum culture, Pseudomonas aeruginosa infection, arterial oxygen pressure, daily dyspnea, C-reactive protein, leukocytes, and the percentage of neutrophils were found to be closely related to bronchiectasis. However, these were not considered risk factors. The evidence of all outcomes was judged as “low” or “very low.” Additional prospective studies are required to elucidate the underlying risk factors and identify effective preventive interventions.

7 May 2021 in Medicine
Verified
Journal Article
Open access
HZHao-Yang Zhang
Hao-Yang Zhang
HHHan Mm Huang
Han Mm Huang
LPLi-Jian Pang
Li-Jian Pang
XLXiao-Dong Lv
Xiao-Dong Lv
WZWei-Dong Zheng
Wei-Dong Zheng
Background: Acute exacerbation is a primary cause of repeated hospitalization and death in chronic obstructive pulmonary disease (COPD) patients. Therefore, how to control the symptoms of COPD at stable stage and reduce the number of acute exacerbation is a hot spot of medical research. Acupoint application (AA) is a significant part of external treatment of traditional Chinese medicine (TCM), Previous researches have reported that AA can be applied to the treatment of COPD. Nevertheless, its effectiveness is still inconclusive. This systematic review (SR) and meta-analysis is designed to appraise its effectiveness and safety for the treatment of patients with COPD. Methods: Eight databases will be systematically retrieved from their inceptions to February 2021. Inclusion criteria are randomized control trials of AA combined with routine western medicine interventions in the treatment of COPD at stable stage. The primary outcomes we focus on comprise clinical effective rate, TCM symptom score, quality of life, dyspnea, exercise capacity, lung function, frequency of acute exacerbation, adverse events. The research screening, data extraction, and risk of bias assessment will be conducted by 2 individuals independently, and divergence will be adjudicated by a third senior investigator. The Stata 13.1 software will be used for meta-analysis. The confidence of evidence will be classified adopting grading of recommendations assessment, development and evaluation (GRADE) algorithm and methodological quality of this SR will be assessed using assessment of multiple systematic reviews-2 (AMSTAR-2) tool. Results: This SR will provide evidence-based medical proof for the treatment of COPD at stable stage by AA combined with conventional western medicine interventions. The findings of this SR will be presented at relevant conferences and submitted for peer-review publication. Conclusions: The findings of this SR will provide up-todated summary proof for evaluating the effectiveness and safety of AA for COPD. Registration number: INPLASY 202140080.

25 September 2020 in Medicine
Verified
Journal Article
Open access
HZHao-Yang Zhang
Hao-Yang Zhang
LPLi-Jian Pang
Li-Jian Pang
XLXiao-Dong Lv
Xiao-Dong Lv
CLChuang Mm Liu
Chuang Mm Liu
MNMing-Hua Mm Nan
Ming-Hua Mm Nan
Background: The therapeutic strategies of idiopathic pulmonary fibrosis (IPF) tend to be comprehensive. Improving the major symptoms and quality of life (QoL) is as important as postponing the process of fibrosis. However, only pirfenidone and nintedanib conditionally recommended by guidelines and no definite proof indicate that they can significantly ameliorate the main symptoms and QoL of IPF sufferers. At present, multiple types of Traditional Chinese Medicine (TCM) interventions alone or in combination with conventional western medicine managements are widespreadly applied in IPF treatment, which seemingly have a promising clinical effect, especially in ameliorating the main symptoms and improving QoL. Subsequently, the number of relevant studies in systematic reviews(SRs) and meta-analyses of randomized controlled trials(RCTs) increased significantly. Hence, we plan to implement an overview to collect, evaluate, and summarize the results of these SRs. Methods: An all-round literature retrieval will be conducted in 9 electronic databases, including PubMed, EMBASE, CINAHL, Cochrane Library, Epistemonikos, CNKI, CBM, Wanfang, and VIP. We will focus on the systematic review and meta-analysis of RCTs for multiple TCM interventions alone or in combination with routine western medicine measures in IPF treatment. The main outcomes we follow with interest include the improvement of major symptoms (cough, dyspnea) and QoL. Secondary outcomes will consist of minor symptoms improvement, clinical total effective rate, lung function, blood gas analysis, 6-minute walk text, adverse events, acute exacerbation, all-cause mortality, and IPF-related mortality. Two reviewers will independently select the SRs satisfactory with the enrolling criteria, extract key characteristics, and datas on predefined form, evaluate methodological quality by AMSTAR-2, ROBIS and PRISMA tools, and the quality of evidences adopting GRADE method. In case of any divergence will be reached an agreement by discussion or adjudicated by a third senior reviewer. We will perform a narrative synthesis of the proofs from SRs included. Results: The findings of this overvew will be presented at relevant conferences and submitted for peer-review publication. Conclusions: We expect to obtain comprehensive and reliable evidence of IPF treated by diversified TCM interventions from the potential standard SRs, which may provide suggestions for future RCTs and SRs. Registration number: INPLASY 202080110

20 August 2023 in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
Verified
Journal Article
Closed access
LPLijian Pang
Lijian Pang
HZHaoyang Zhang
Haoyang Zhang
JWJingyu Wang
Jingyu Wang
XMXiande Ma
Xiande Ma
NZNingzi Zang
Ningzi Zang
XLXiaodong Lv
Xiaodong Lv
Background: Nowadays, non-effective drugs have been confirmed for idiopathic pulmonary fibrosis (IPF) therapy. Previous experimental studies have shown that Shenlong Jianji (SLJJ) is a potentially effective Chinese herbal formula for IPF therapy. However, more research is needed to assess its therapeutic targets and intervention mechanisms. Methods: Active ingredients, corresponding targets of active ingredients and disease targets were assessed. Based on interrelation between active ingredient targets and disease targets, gene enrichment analyses were performed to assess the potential pharmacological mechanism of SLJJ for IPF. Overall, 144 Wistar adult rats were randomly divided into six groups (control group, model group, prednisone group and SLJJ high, medium, and low doses groups). Rats were given bleomycin (BLM) to trigger IPF. After treatment with corresponding medicine, histopathology changes of lung tissue were assessed using hematoxylin-eosin staining and masson's trichrome staining. Concentration of hydroxyproline (HYP) in lung tissue was analyzed using chloramine hydrolysis method. Lung function and blood gas analysis of rats in each group were also assessed in this study. Interferon-γ (IFN-γ) and Interleukin-4 (IL-4) content in serum were assessed using enzyme-linked immunosorbent assay. Protein and gene expressions of IFN-γ, IL-4, transforming growth factor-β1 (TGF-β1), transforming growth factor-βRII (TGF-βRII), Smad3, and Smad7 in lung tissue were assayed using western blotting and realtime-polymerase chain reaction. Results: 126 signaling pathways were obtained by gene enrichment analysis. Overall, SLJJ groups showed significant improvement on histopathology assessment and reduced HYP content in lung tissue compared to model group. SLJJ can also improve lung function and blood gas analysis results. Additionally, there was a decrease on IL-4 level and increase on IFN-γ level in serum, down-regulating IL-4, TGF-β1, TGF-βRII, Smad3 protein and mRNA expressions and up-regulating IFN-γ and Smad7 protein and mRNA expressions in lung tissue. Conclusions: Our findings suggest that SLJJ is a valid formula to alleviate BLM-induced IPF, while its partial mechanism might mediate by coordinating the IFN-γ/IL-4 balance and regulating the TGF-β1/Smads signaling pathways. The potential targets predicted by network pharmacology warrant further validation.

20 October 2023 in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
Verified
Journal Article
Closed access
YLYuan-Yu Liang
Yuan-Yu Liang
YLYong-Ming Liu
Yong-Ming Liu
DMDong-Yu Min
Dong-Yu Min
JWJia-Ran Wang
Jia-Ran Wang
LZLing-Yun Zhu
Ling-Yun Zhu
XLXiao-Dong Lv
Xiao-Dong Lv
Background: Chronic obstructive pulmonary disease (COPD) and mild cognitive impairment (MCI) are two conditions that are closely associated with worse progression and prognosis. However, the potential common pathogenetic mechanisms and genetic modulators that link these two conditions remain elusive. This study aimed to investigate the shared differentially expressed genes (DEGs) to reveal the co-genetic features and molecular mechanisms between COPD and MCI. Methods: Overlapping DEGs were identified from the COPD dataset (GSE148004) and the MCI dataset (GSE63060). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted based on the overlapping genes to annotate the biological signaling pathways. Then, a protein-protein interaction (PPI) network was constructed using the STRING database and Cytoscape software to screen out the key subnetworks and hub genes. Finally, the hub genes were validated in external datasets (GSE11784, GSE106986, and GSE63061) to enhance the reliability and efficacy of the results. Results: In total, 26 overlapping DEGs in COPD and MCI, as well as crucial pathways such as adenosine triphosphate (ATP) synthesis coupled electron transport, respiratory electron transport chain, and oxidative phosphorylation were obtained. Through the constructed PPI network, 12 hub genes were identified, including ATP5C1, ATP5J, ATP5O, cytochrome c oxidase subunit 7C (COX7C), histidine triad nucleotide binding protein 1 (HINT1), NADH:ubiquinone oxidoreductase subunit A1 (NDUFA1), NDUFB2, NDUFA4, NDUFS4, NDUFS5, translocase of outer mitochondrial membrane 7 (TOMM7), and ubiquinol-cytochrome c reductase complex III subunit VII (UQCRQ), along with their enriched biological pathways, oxidative phosphorylation, and ATP metabolic process. The validation of hub genes in external datasets showed that ATP5C1, COX7C, NDUFA1, and NDUFS5 might be the pivotal therapeutic targets. Conclusions: To uncover the underlying mechanisms between COPD and MCI, this study identified the hub genes and corresponding regulatory mitochondrial pathways, which might provide promising insights and novel strategies for further research.

19 April 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JPJiaxiang Pan
Jiaxiang Pan
YLYue Li
Yue Li
XWXize Wu
Xize Wu
XPXue Pan
Xue Pan
CLChuang Liu
Chuang Liu
XLXiaodong Lv
Xiaodong Lv